Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (ORGO) is a leader in regenerative medicine, specializing in advanced wound care and surgical biologics. This page aggregates all official company announcements, press releases, and material developments for investors and industry observers.
Find updates on quarterly earnings, product innovations, regulatory milestones, and clinical trial progress. Our curated feed ensures timely access to information affecting ORGO's position in regenerative therapies and sports medicine markets.
Key areas include bioactive wound care solutions, FDA filings, partnership announcements, and manufacturing updates. All content is sourced directly from company communications to maintain accuracy and compliance.
Bookmark this page for easy access to Organogenesis' latest developments. Check back regularly for updates on their pioneering work in tissue repair technologies and healthcare market strategies.
Organogenesis Holdings (Nasdaq: ORGO) reported Q3 2025 net product revenue of $150.5M, up 31% year-over-year, driven by Advanced Wound Care ($141.5M, +31%) and Surgical & Sports Medicine ($9.0M, +25%). Q3 net income was $21.6M versus $12.3M in Q3 2024; adjusted EBITDA was $30.1M. Nine-month net product revenue declined 5% to $338.0M and the nine-month operating loss was $18.6M. Cash and equivalents were $64.4M at Sept 30, 2025. For FY2025 the company updated guidance to $500.0M–$525.0M in net product revenue and adjusted EBITDA of $45.5M–$68.3M.
Organogenesis (Nasdaq: ORGO) applauded CMS’s finalization of payment reform for skin substitutes/CTPs under the CY 2026 Physician Fee Schedule announced Nov. 3, 2025.
The company highlighted that CMS finalized FDA classifications and a per centimeter-square payment methodology for both physician office and hospital outpatient settings, and said CMS recognized the clinical differentiation of PMA products, which the company believes will increase access and support higher payment and expanded access for PMA technologies. Organogenesis reiterated its multi-decade leadership and said its evidence-based portfolio positions it well for the skin substitutes market in 2026 and beyond.
The release contains forward-looking statements and cautions that actual outcomes are subject to risks and uncertainties described in the company’s SEC filings.
Organogenesis (Nasdaq: ORGO) announced inducement equity awards tied to its newly hired Chief Technology Officer, Michael Catarina, effective October 29, 2025.
The Board granted 82,542 non‑statutory stock options (NSOs) with an exercise price of $4.17 per share and 47,962 restricted stock units (RSUs). Both awards vest in substantially equal annual installments over four years beginning October 20, 2025, subject to continued employment. Although granted outside the 2018 Equity Incentive Plan, the awards are governed by that plan's terms and the related award agreements.
The awards were made as an inducement material to Mr. Catarina’s acceptance of employment pursuant to Nasdaq Listing Rule 5635(c)(4).
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its Q3 2025 earnings release for November 6, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day, featuring a corporate update and Q&A session. Investors can join via webcast or teleconference using the dial-in numbers 800-715-9871 (US) or 646-307-1963 (international) with access code 9073428. The webcast will be available on the company's investor relations website for approximately one year.
Organogenesis (NASDAQ: ORGO) announced that its second Phase 3 trial for ReNu®, a treatment for knee osteoarthritis (OA), did not meet its primary endpoint despite showing improved pain reduction. The trial demonstrated a numerical improvement of -0.51 favoring ReNu (p=0.0393) compared to saline, falling short of the p=0.023 target threshold.
Key highlights include baseline pain reduction of -6.9 at six months in the second Phase 3 study, improving from -6.0 in the first Phase 3 study. The company maintains confidence in ReNu's potential and plans to request a pre-BLA meeting with the FDA by end of October to discuss submission pathway, leveraging combined efficacy analysis from both Phase 3 studies.
ReNu has been studied in three large RCTs with over 1,300 patients and has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical & Sports Medicine markets, has announced its participation in two major healthcare investor conferences in September.
Management will present at the Cantor Fitzgerald Global Healthcare Conference on September 3 at 2:10 p.m. ET and the Morgan Stanley Global Healthcare Conference on September 10 at 2:35 p.m. ET. Both events will take place in New York City and feature fireside chat sessions that will be available via webcast on the company's investor relations website for approximately 30 days after the events.
Organogenesis Holdings (NASDAQ: ORGO) reported Q2 2025 financial results showing a decline in performance. The company posted net product revenue of $100.8 million, down 23% from $130.2 million in Q2 2024. The Advanced Wound Care segment saw a 25% decrease to $92.7 million, while Surgical & Sports Medicine revenue increased 16% to $8.1 million.
The company reported a net loss of $9.4 million ($0.10 per share), an improvement from a $17.0 million loss in Q2 2024. Adjusted EBITDA turned negative at $(3.6) million, compared to positive $15.6 million in the prior year. The company maintained a strong balance sheet with $73.7 million in cash and no debt.
For full-year 2025, Organogenesis updated guidance, projecting revenue between $480-$510 million, representing flat to 6% growth, with net income ranging from $(6.4) million to $16.4 million.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its second quarter fiscal year 2025 earnings release for August 7, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update. Investors can join via webcast or teleconference using the number 800-715-9871 (646-307-1963 for international) with access code 634899. The webcast will be available on the company's investor relations website for approximately one year.
Organogenesis (Nasdaq: ORGO), a regenerative medicine company, has expressed support for the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes in CY 2026. The proposal introduces a per centimeter square payment system based on FDA classification across both physician office and hospital outpatient settings.
CEO Gary S. Gillheeney highlighted that the new structure aims to reduce system abuse and Medicare spending while ensuring consistent payment across care sites. The proposal notably recognizes PMA products' clinical differentiation and seeks to expand access to innovative wound healing technologies that help reduce amputations and complications.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
